PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
Article content
TOKYO — PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor.
Article content
'We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor' said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. 'Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in humans as well. Our preclinical animal models (LDL-R KO mice; HoFH model, and high-fat diets induced MASH model mice) have shown that PRD001 lowers blood and liver lipids and suppresses the progression of fatty liver and atherosclerosis with no adverse events. PRD001 has the potential to be the first-in-class effective and safe oral therapy for HoFH patients suffering from no or extremely low LDL receptor activity.'
Article content
This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers. More information can be found at NCT07034183.
Article content
PRD001 is a first-in-class, orally available small molecule SOAT2-selective inhibitor. It uniquely controls three key pathways of lipid metabolism; cholesterol synthesis in the liver, cholesterol absorption in the small intestine, and uptake of blood LDL-C with a single drug, leading to a potent reduction in a blood LDL-C level independent of the LDL receptor.
Article content
This research and development is supported by Japan Agency for Medical Research and Development (AMED) under Strengthening Program for Pharmaceutical Startup Ecosystem (Project title: ' Development of First-in-class oral lipid metabolism regulator PRD001 and POC obtained for lipid metabolism disorder ').
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 hours ago
- Globe and Mail
WHO expert group fails to find a definitive answer for how COVID-19 began
An expert group charged by the World Health Organization to investigate how the COVID-19 pandemic started released its final report Friday, reaching an unsatisfying conclusion: Scientists still aren't sure how the worst health emergency in a century began. At a press briefing on Friday, Marietjie Venter, the group's chair, said that most scientific data supports the hypothesis that the new coronavirus jumped to humans from animals. That was also the conclusion drawn by the first WHO expert group that investigated the pandemic's origins in 2021, when scientists concluded the virus likely spread from bats to humans, via another intermediary animal. At the time, WHO said a lab leak was 'extremely unlikely.' Venter said that after more than three years of work, WHO's expert group was unable to get the necessary data to evaluate whether or not COVID-19 was the result of a lab accident, despite repeated requests for hundreds of genetic sequences and more detailed biosecurity information that were made to the Chinese government. 'Therefore, this hypothesis could not be investigated or excluded,' she said. 'It was deemed to be very speculative, based on political opinions and not backed up by science.' She said that the 27-member group did not reach a consensus; one member resigned earlier this week and three others asked for their names to be removed from the report. Five years ago, we predicted how COVID-19 would change our world. Here's what we got right – and wrong Venter said there was no evidence to prove that COVID-19 had been manipulated in a lab, nor was there any indication that the virus had been spreading before December 2019 anywhere outside of China. 'Until more scientific data becomes available, the origins of how SARS-CoV-2 entered human populations will remain inconclusive,' Venter said, referring to the scientific name for the COVID-19 virus. WHO Director-General Tedros Adhanom Ghebreyesus said it was a 'moral imperative' to determine how COVID began, noting that the virus killed at least 20 million people, wiped at least US$10 trillion from the global economy and upended the lives of billions. Last year, the AP found that the Chinese government froze meaningful domestic and international efforts to trace the virus' origins in the first weeks of the outbreak in 2020 and that WHO itself may have missed early opportunities to investigate how COVID-19 began. U.S. President Donald Trump has long blamed the emergence of the coronavirus on a laboratory accident in China, while a U.S. intelligence analysis found there was insufficient evidence to prove the theory. Chinese officials have repeatedly dismissed the idea that the pandemic could have started in a lab, saying that the search for its origins should be conducted in other countries. Last September, researchers zeroed in on a short list of animals they think might have spread COVID-19 to humans, including racoon dogs, civet cats and bamboo rats.
CBC
20 hours ago
- CBC
Origins of COVID-19 still unclear according to final report from WHO expert group
An expert group charged by the World Health Organization to investigate how the COVID-19 pandemic started released its final report on Friday, reaching an unsatisfying conclusion: Scientists still aren't sure how the worst health emergency in a century began. At a news briefing, Marietjie Venter, the group's chair, said that most scientific data supports the hypothesis that the new coronavirus jumped to humans from animals. That was also the conclusion drawn by the first WHO expert group that investigated the pandemic's origins in 2021, when scientists concluded the virus likely spread from bats to humans, via another intermediary animal. At the time, WHO said a lab leak was "extremely unlikely." Venter said that after more than three years of work, WHO's expert group was unable to get the necessary data to evaluate whether or not COVID-19 was the result of a lab accident, despite repeated requests for hundreds of genetic sequences and more detailed biosecurity information that were made to the Chinese government. "Therefore, this hypothesis could not be investigated or excluded," she said. "It was deemed to be very speculative, based on political opinions and not backed up by science." She said that the 27-member group did not reach a consensus; one member resigned earlier this week and three others asked for their names to be removed from the report. Venter said there was no evidence to prove that COVID-19 had been manipulated in a lab, nor was there any indication that the virus had been spreading before December 2019 anywhere outside of China. "Until more scientific data becomes available, the origins of how SARS-CoV-2 entered human populations will remain inconclusive," Venter said, referring to the scientific name for the COVID-19 virus. WHO Director General Tedros Adhanom Ghebreyesus said it was a "moral imperative" to determine how COVID began, noting that the virus killed at least 20 million people, wiped at least $10 trillion US from the global economy and upended the lives of billions. Last year, The Associated Press found that the Chinese government froze meaningful domestic and international efforts to trace the virus's origins in the first weeks of the outbreak in 2020 and that WHO itself may have missed early opportunities to investigate how COVID-19 began. U.S. President Donald Trump has long blamed the emergence of the coronavirus on a laboratory accident in China, while a U.S. intelligence analysis found there was insufficient evidence to prove the theory. Chinese officials have repeatedly dismissed the idea that the pandemic could have started in a lab, saying that the search for its origins should be conducted in other countries.
National Post
a day ago
- National Post
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
Article content TOKYO — PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. Article content 'We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor' said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. 'Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in humans as well. Our preclinical animal models (LDL-R KO mice; HoFH model, and high-fat diets induced MASH model mice) have shown that PRD001 lowers blood and liver lipids and suppresses the progression of fatty liver and atherosclerosis with no adverse events. PRD001 has the potential to be the first-in-class effective and safe oral therapy for HoFH patients suffering from no or extremely low LDL receptor activity.' Article content This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers. More information can be found at NCT07034183. Article content PRD001 is a first-in-class, orally available small molecule SOAT2-selective inhibitor. It uniquely controls three key pathways of lipid metabolism; cholesterol synthesis in the liver, cholesterol absorption in the small intestine, and uptake of blood LDL-C with a single drug, leading to a potent reduction in a blood LDL-C level independent of the LDL receptor. Article content This research and development is supported by Japan Agency for Medical Research and Development (AMED) under Strengthening Program for Pharmaceutical Startup Ecosystem (Project title: ' Development of First-in-class oral lipid metabolism regulator PRD001 and POC obtained for lipid metabolism disorder '). Article content Article content Article content Article content Article content
